51
|
Comont T, Delavigne K, Challan-Belval T, Ollier S, Brechemier D, Adoue D, Beyne-Rauzy O. 367 Durable response after lenalidomide discontinuation in del(5q) low risk MDS. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70369-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
52
|
Prévot G, Delavigne K, Cougoul P, Comont T, Brechemier D, Prudhomme L, Adoue D, Beyne-Rauzy O. 186 Interstitial lung disease: Uncommon but potentially severe effect of hypomethylating agents. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70188-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
53
|
Farah C, Bulai Livideanu C, Jegu J, Paul C, Viraben R, Lamant L, Delavigne K, Adoue D, Laurent G, Beyne Rauzy O. Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome. J Eur Acad Dermatol Venereol 2011; 24:1171-5. [PMID: 20202054 DOI: 10.1111/j.1468-3083.2010.03614.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Skin manifestations associated with myelodysplastic syndrome (MDS) may reveal bone marrow transformation into acute myeloid leukaemia. OBJECTIVE The objective of this study was to assess the prevalence of skin manifestations associated with MDS. In addition, we evaluated the risk of acute myeloid leukaemia transformation associated with skin manifestations. METHODS We studied a cohort of 157 patients with primary MDS followed up prospectively for a median of 44 months. Skin lesions were prospectively assessed as part of medical examination every 6 months by a board certified dermatologist. Survival analyses were performed to assess the association between the presence of skin lesions and the risk of acute myeloid leukaemia. RESULTS Fifteen patients (9.55%) experienced skin lesions previously reported as associated with MDS. These were neutrophilic dermatosis (7, 4.46%), specific lesions (5, 3.18%), cutaneous vasculitis (2, 1.27%) and Behçet disease (1, 0.63%). Survival analysis showed that the risk of transformation into acute myeloid leukaemia was slightly but not significantly increased in patients with skin lesions as compared with patients without skin lesions with a relative risk of 2.08 (95% CI 0.92-4.67). CONCLUSION The prevalence of skin lesions, mostly neutrophilic dermatosis and specific lesions, is relatively high in patients with MDS. There is a trend for a higher risk of transformation into acute myeloid leukaemia in patients with skin lesions.
Collapse
|
54
|
Moulis G, Delavigne K, Alvarez M, Brassat D, Bonneville F, Massip P, Adoue D. [Chronic headaches]. Rev Med Interne 2010; 32:46-7. [PMID: 21145627 DOI: 10.1016/j.revmed.2010.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2010] [Accepted: 04/10/2010] [Indexed: 11/18/2022]
|
55
|
Pasquali JL, Bletry O, Hachulla E, Mariette X, Adoue D, Lambert M, Pineda L, Zhong Z, Hough D, Freimuth W. Le belimumab, inhibiteur spécifique de BlyS, réduit l’activité de la maladie, les poussées et l’utilisation de prednisone chez des patients lupiques : résultats d’efficacité groupés des études de phase 3 BLISS-52 et BLISS-76. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
56
|
Moulis G, François M, Laffont MA, Adoue D, Montastruc JL. Médicaments inducteurs de purpura thrombopénique auto-immun dans la banque nationale de pharmacovigilance. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
57
|
Adoue D, Grivel T. Immunoglobulines : protéines aux potentiels thérapeutiques multiples dans les déficits immunitaires. Rev Med Interne 2010; 31:H9-11. [DOI: 10.1016/s0248-8663(10)70007-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
58
|
Forgues ML, Giron J, Hitzel A, Astudillo L, Julian A, Payoux P, Pugnet G, Adoue D, Prudhomme L, Degraeve F, Arlet P, Sailler L. Aortite inflammatoire : performances diagnostiques de la mesure de l’épaisseur de la paroi aortique par le scanner thoraco-abdominal avec injection de produit de contraste de routine. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
59
|
Grimaldi-Bensouda L, Khellaf M, Viallard JF, Adoue D, Hacini M, Magy-Bertrand N, Morin AS, Pan-Petesh B, Michel M, Abenhaim L, Godeau B. Epidémiologie du purpura thrombopénique immunologique de l’adulte en France. À propos d’une étude multicentrique prospective portant sur 171 malades. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
60
|
Sibon D, Deligny C, Sarrault-Raynaud F, Launay D, Durand JM, Philippe P, Quere I, Adoue D, Roblot P, Constans J, Durant C, Farge D. Activité française comparée à l’activité européenne pour greffe de cellules souches hématopoïétiques dans le traitement des maladies auto-immunes. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
61
|
Edouard S, Astudillo L, Pugnet G, Adoue D, Didier A, Cantagrel A, Paul C, Arlet-Suau E, Arlet P, Sailler L. Traitements médicamenteux de la sarcoïdose évaluation chez 156 atients au CHU de Toulouse. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
62
|
Lourari S, Herve C, Doffoel-Hantz V, Meyer N, Bulai-Livideanu C, Viraben R, Maza A, Adoue D, Bedane C, Paul C. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 2010; 25:1238-40. [DOI: 10.1111/j.1468-3083.2010.03889.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
63
|
Hervier B, Hamidou M, Uzunhan Y, Hachulla E, Adoue D, Stanciu R, Fautrel B, Arlet P, Cacoub P, Musset L, Amoura Z, Benveniste O. Comparaison du syndrome des antisynthétases avec anticorps anti-PL12 (26 patients) avec le syndrome des antisynthétases avec anticorps anti-JO1 (50 patients). Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
64
|
Moulis G, Delavigne K, Dutertre M, François M, Picard M, Cougoul P, Beyne-Rauzy O, Montastruc JL, Adoue D. L’ézétimibe, un nouveau médicament potentiellement inducteur de purpura thrombopénique idiopathique. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
65
|
Hervier B, Wallaert B, Hachulla E, Adoue D, Lauque D, Audrain M, Camara B, Fournie B, Couret B, Hatron PY, Dubucquoi S, Hamidou M. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford) 2010; 49:972-6. [DOI: 10.1093/rheumatology/kep455] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
66
|
Moulis G, Delavigne K, Martin-Blondel G, Huguet F, Fortenfant F, Beyne-Rauzy O, Adoue D. Prévalence d’une thrombopénie chez 27 patients atteints de syndrome des antiphospholipides. Étude de la survenue de thrombopénie et de lupus à 3 ans. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.10.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
67
|
Deligny C, Martin T, Keshmandt H, Durand JM, Sarrot-Reynauld F, Philippe P, Adoue D, Roblot P, Quere I, Constans J, Launay D, Farge D. L’essai européen ASTIS : 151 patients (48 en France avec le soutien du GFRS et de l’AFS) inclus en 9 ans. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.10.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
68
|
Moulis G, Martin-Blondel G, Delavigne K, Periquet B, Beyne-Rauzy O, Adoue D. Statut martial des patients anémiques atteints de maladie de Horton. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.10.417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
69
|
Moulis G, Delavigne K, Martin-Blondel G, Huguet F, Fortenfant F, Beyne-Rauzy O, Adoue D. Thrombopénie auto-immune et syndrome des anti-phospholipides : comparaison du profil des anticorps antiphospholipides à partir de 120 patients. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.10.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
70
|
Marie I, Lahaxe L, Benveniste O, Delavigne K, Adoue D, Mouthon L, Hachulla E, Constans J, Tiev K, Diot E, Levesque H, Boyer O, Jouen F. Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2009; 162:337-44. [PMID: 19845665 DOI: 10.1111/j.1365-2133.2009.09484.x] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND To date, no series has analysed long-term outcome in patients with polymyositis/dermatomyositis (PM/DM) with anti-PM-Scl antibody. OBJECTIVES The aims of the present study were: (i) to assess clinical features and long-term outcome, including organ complications, functional course and mortality rate, in patients with isolated PM/DM with anti-PM-Scl antibody; and (ii) to evaluate prevalence, characteristics and long-term outcome of interstitial lung disease (ILD) in patients with isolated PM/DM with anti-PM-Scl antibody. METHODS The medical records of 20 consecutive patients with isolated PM/DM with anti-PM-Scl antibody were reviewed. RESULTS Two patients (10%) achieved remission of PM/DM, whereas 14 (70%) improved and four (20%) had a worsened clinical status. Short-term recurrences (during tapering of therapy) occurred in nine patients and long-term recurrences (after discontinuation of therapy) in three patients. Moreover, patients with PM/DM with anti-PM-Scl antibody exhibited severe complications, as follows: oesophageal involvement (n = 4) requiring enteral feeding in three cases, ventilatory insufficiency (n = 3) requiring mechanical ventilation in two cases; three other patients had cancer. Interestingly, patients with PM/DM with anti-PM-Scl antibody often presented symptoms that are usually found in antisynthetase syndrome, i.e. hyperkeratotic rhagadiform hand symptoms (n = 2; 10%), Raynaud's phenomenon (n = 8; 40%), arthralgia/arthritis (n = 7; 35%) and ILD (n = 12; 60%). In our cohort, the associated ILD often required combined therapy of steroids and immunosuppressive agents. CONCLUSIONS Our series suggests that the presence of anti-PM-Scl antibody is not a good prognostic factor in patients with PM/DM, as there appears to be an association with lung and oesophageal involvement; in addition, anti-PM-Scl antibody may coexist with malignancy in patients with PM/DM. Furthermore, anti-PM-Scl antibody-positive patients with PM/DM often exhibit 'mechanic's hands', Raynaud's phenomenon and joint involvement. Our latter findings raise the possibility that the immunogenetic background influences the autoantibody status of these patients; HLA-DR3 has, in fact, been found in association with antisynthetase syndrome antibodies and with anti-PM-Scl antibodies.
Collapse
|
71
|
Martin-Blondel G, Moulis G, Cassaing S, Chabrol A, Ollier S, Beyne-Rauzy O, Adoue D. Un diagnostic « alternative » d’aspergillome sinusien : l’alternariose. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.03.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
72
|
Moulis G, Martin-Blondel G, Forgues M, Brassat D, Adoue D. Atteinte du système nerveux central au cours de la sclérodermie systémique. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.03.154] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
73
|
Challan-Belval T, Reutenauer S, Martin-Blondel G, Sorin L, Laurent G, Adoue D, Beyne-Rauzy O. P096 Varicella-zoster virus meningoencephalitis during the course of hypomethylating agent therapy in high risk myelodysplastic syndrome. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70176-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
74
|
Moulis G, Reutenauer S, Bart-Delabesse E, Debent L, Delavigne K, Laurent G, Adoue D, Beyne-Rauzy O. P094 Impact of an educational program at the onset of new therapy (hypomethylating agent) in myelodysplastic syndromes: a pilot study with positive effects on both patients and physicians. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70174-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
75
|
Divies A, Herin F, Delavigne K, Bart-Delabesse E, Dastugue N, Laurent G, Adoue D, Beyne-Rauzy O. P093 Link between occupational exposure to heavy metals and high risk myelodysplastic syndromes. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70173-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|